Director/PDMR Shareholding

Released : 04 Aug 2023 04:16:00

RNS Number : 4108IChemring Group PLC04 August 2023

4 August 2023

Chemring Group PLC

Grant of options

Chemring Group PLC ("Chemring" or "the Company") announces that it has today granted, pursuant to The Chemring Group 2018 UK Sharesave Plan, options over 7,894 1p ordinary shares in the capital of the Company to Sarah Ellard, a director of the Company. The options will be exercisable in three years time at an exercise price of 228p per share. 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 Sarah Ellard

2

Reason for the notification

a)

Position/status

Director/PDMR

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Chemring Group PLC

b)

LEI

213800U9A54VQJ5P2J41

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Options over 1p ordinary shares

GB00B45C9X44

b)

Nature of the transaction

Grant of options under The Chemring Group 2018 UK Sharesave Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

228p

7,894

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

4 August 2023

f)

Place of the transaction

UK

For further information:

Chemring Group PLC

Sarah Ellard

Group Legal Director

+44 (0)1794 463420
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDDSHFLFLETEISIIV